Navigation Links
Jefferson researchers mirror human response to bacterial infection and resolution in mice
Date:12/14/2011

PHILADELPHIAImitating human diseases using an animal model is a difficult task, but Thomas Jefferson University researchers have managed to come very close.

Reporting in the Proceedings of the National Academy of Sciences, a team of Jefferson immunologists found that a specialized "human immune system" mouse model closely mimics a person's specific response and resolution of a tick-borne infection known as relapsing fever, caused by the bacteria Borrelia hermsii.

The response is so strikingly similar that it gives good reason for researchers to apply the strategy to a host of other infections to better understand how the immune system attempts to fights them which could ultimately lead to precise treatment and prevention strategies.

"This is first time an interaction of an infectious agent with a host, the progression of the disease and its eventual resolution recapitulates what you would see in a human being," said Kishore R. Alugupalli, Ph.D., Assistant Professor of Microbiology and Immunology at Thomas Jefferson University and the Kimmel Cancer Center at Jefferson. "Our model is not only a susceptible model, but it actually tells us how the human immune system is functionally working. That is the big difference from the previous studies."

What really surprised the team is that the mouse physiological environment was able to facilitate the development of human B1-like cells, which is specialized type of antibody producing systems used to fight infection due to a variety of bacterial pathogens, including Pneumococcus and Salmonella.

In the study, researchers transferred hematopoietic stem cells from human umbilical cord blood into mice lacking their own immune system. This resulted in development of a human immune system in these mice. These "human immune system" (HIS) mice were then infected to gauge response.

According to the authors, an analysis of spleens and lymph nodes revealed that the mice developed a population of B1b-like cells that may have fought off the infection. Researchers also observed that reduction of those B cells resulted in recurrent episodes of bacteremia, the hallmark of relapsing fever.

"The B1b cells in humans had been speculated, but never confirmed," said co-author Timothy L. Manser, Ph.D., Professor and Chair of the Department of Microbiology and Immunology at Jefferson. "We found that in mice, the B1b cell subset is critically important for resolution of this type of bacterial infection."

"This would indicate that there is a functional equivalent of the subset in humans that has not been previously recognized," he added.

The mouse model with relapsing fever recapitulates many of the clinical manifestations of the disease and has previously revealed that T cell-independent antibody responses are required to resolve the bacteria episodes. However, it was not clear whether such protective humoral responses are mounted in humans.

"It's an amazing platform that could be used to really study how the human B1 cells could work against a variety of bacterial and viral infections," said Dr. Alugupalli.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University receives Science Centers QED Award for pancreatic cancer research
2. Jefferson researchers study outcomes of carotid artery stenting following prior carotid procedure
3. Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
4. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
5. Jefferson physician named an Educator of the Year by the Assocociation of Residents in Radiation Oncology
6. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
7. Thomas Jefferson University and hospitals tasked to find new radiation drugs
8. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
9. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
10. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
11. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
(Date:12/7/2016)... ... , ... “Walking With God: Inspirational Lessons from My Life's Journey”: a ... aware of God's direction in their lives. “Walking With God: Inspirational Lessons from My ... church leader. , Sanford says, “I enjoy sharing the true stories in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 According to responses ... more than one-third (38%) of patients with non-small cell lung ... growth factor receptor (EGFR) genetic mutation status. The findings of ... LBA ID #6067 #P3.02b ) at the 2016 ... Austria . The survey results revealed an ...
(Date:12/7/2016)... Boehringer Ingelheim today announced that the ... malignant pleural mesothelioma (MPM) met its primary endpoint ... the 17 th IASLC World Conference on ... showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful clinical ... significantly improved PFS (9.4 vs 5.7 months). Preliminary ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
Breaking Medicine Technology: